Phase 3 study of extended-release injectable naltrexone for treatment of opioid dependence (En)
November 16, 2009 Alkermes Inc. announced positive preliminary results from a Phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. This six month, randomized, multi-center study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients...
Διαβασε περισσότερα